Abstract

   Using of drugs have insufficient therapeutic effects on many diseases including cancer. The side effects derived from anti-tumor compounds are a result of their low specificity. Cancer is the major public burden all over the world. Anticancer drug developments from natural biological resources are ventured throughout the world. Many active principles produced by animals, plants and microorganisms have been employed in the development of new drugs to treat diseases such as great potential as anti-tumor agents. Wasp venoms are complex mixtures of pharmacologically and biochemically active components such as biogenic amines, peptides and proteins have been studied. Many researchers designed a new therapy based peptide binding of several amino acids from wasp venom for its potential use against breast cancer. This peptide has the ability to form pores in the cell plasma membrane, penetrate into the cell and finally, cause its death. Many bioactive substances were identified from wasp venom. These peptides showed anticancer, antimicrobial activities against bacteria and fungi. The present work reports the structural and functional characterization of the bioactive proteins and peptides in wasp venoms for cancer and microbial therapy.

Keywords: Cancer Therapy; Microbile; Wasp Venom; Mastoparan; Peptides

References

1. Siegel R., et al. “Cancer statistics”. CA: A Cancer Journal for Clinicians 62 (2012): 10-29.
2. Baskar R., et al. “Cancer and radiation therapy: Current advances and future directions”. International Journal of Medical Sciences 9 (2012): 193-199.
3. De Graaf DC., et al. “Bee, wasp and ant venomics pave the way for a component-resolved diagnosis of sting allergy”. Journal of Proteomics 72 (2009): 145-154.
4. Habermann E. “Bee and wasp venoms”. Science 177 (1972): 314-322. 
5. Hancock RE., et al. “Cationic bactericidal peptides”. Advances in Microbial Physiology 37 (1995): 135-175.
6. Higashijima T., et al. “NMR saturation transfer and line shape analyses of cyclic tetradepsipeptide AM toxin II: conformational equilibrium with very unequal populations”. FEBS Letters 105 (1979): 337-340.
7. Nakajima T. “Biochemistry of vespid venoms”. In: Tu AT, editor. Handbook of Natural Toxins. Marcel Dekker; New York, USA (1984): 109-133.
8. Yang H., et al. “A phospholipase A1 platelet activator from the wasp venom of Vespa magnifica (Smith)”. Toxicon 51 (2008): 289-296.
9. Piek T. “Pharmacology of hymenoptera venom”. In: Tu AD, editor. Handbook of Natural Toxins. Marcel Dekker; New York, USA 2 (1984): 135-185.
10. Xu X., et al. “The mastoparanogen from wasp”. Peptides 27 (2006b): 3053-3057.
11. Argiolas A and Pisano JJ. “Bombolitins, a new class of mast cell degranulating peptides from the venom of the bumblebee Megabombus pennsylvanicus”. Journal of Biological Chemistry 260 (1985): 1437-1444.
12. Nakajima T., et al. “Amphiphilic peptides in wasp venom”. Biopolymers 25 (1986): S115-S121.
13. Hancock RE., et al. “Cationic bactericidal peptides”. Advances in Microbial Physiology 37 (1995): 135-175.
14. Wu M and Hancock RE. “Interaction of the cyclic antimicrobial cationic peptide bectenecin with the outer and cytoplasmic membrane”. Journal of Biological Chemistry 274 (1999): 29-35.
15. Liu X., et al. “A novel bradykinin-like peptide from skin secretions of the frog, Rana nigrovittata”. Journal of Peptide Science 14 (2008): 626-630.
16. Hirai Y., et al. “A new mast cell degranulatin peptide “mastoparano” in the venom of Vespula lewisii”. Chemical and Pharmaceutical Bulletin 27 (1979): 1942-1944.
17. Raghuraman H., et al. “A membrane-active peptide with diverse functions”. Bioscience Reports 27 (2007): 189-223.
18. Blazquez PS and Garzon J. “Mastoparan reduces the supraspinal analgesia mediated by lX/6-opioid receptors in mice”. European Journal of Pharmaceutical Sciences 258 (1994): 159-162.
19. Zhang P., et al. “Mastoaparan-7 rescues botulinum toxin-A poisoned neurons in a mouse spinal cord cell culture model”. Toxicon 76 (2013): 37-43.
20. Souza BM., et al. “Investigating the effect of different positioning of lysine residues along the peptide chain of mastoparans for their secondary structures and biological activities”. Amino Acids (2011).
21. Silva AVR., et al. “The effects of C-terminal amidation of mastoparans on their biological actions and interactions with membrane-mimetic systems”. Biochimica et Biophysica Acta 1838 (2014):  2357-2368.
22. Fanghänel S., et al. “Structure analysis and conformational transitions of the cell penetrating peptide transportan 10 in the membrane-bound state”. Plos one 9 (2014):  e99653.
23. Chen Y and Liu L. “Modern methods for delivery drugs across the blood-brain barrier”. Advanced Drug Delivery Reviews 64 (2012): 640-655.
24. Pooga M., et al. “Cell penetration by transportan”. The FASEB Journal 12 (1998):  67-77.
25. Yandek LE., et al. “Mechanism of the cell-penetrating peptide transportan 10 permeation of lipid bilayers”. Biophysical Journal 92 (2007):  2434-2444.
26. Webling KE., et al. “Galanin receptors and ligands”. Frontiers in Endocrinology (Lausanne) 3 (2012): 1-14.
27. Counts SE., et al. “Galanin hyperinnervation upregulates choline acetyltransferase expression in cholinergic basal forebrain neurons in Alzheimer’s disease”. Neurodegenerative Diseases 5 (2008): 228-231.
28. Montecucco C and Schiavo G. “Mechanism of action of tetanus and botulinum neurotoxins”. Molecular Microbiology 13 (1995): 1-8.
29. Simpson L. “The life story of a botulinum toxin molecule”. Toxicon 68 (2013): 40. 
30. Jones S and Howl J. “Biological applications of the receptor mimetic peptide Mastoparan”. Current Protein and Peptide Science 7 (2006): 501-508.
31. Todokoro Y., et al. “Structure of tightly membrane-bound Mastoparan-X, a G-protein-activating peptide, determined by solid-state NMR”. Biophysical Journal 91 (2006): 1368-1379.
32. Higashijima T., et al. “Mastoparan, a peptide toxin from wasp venom, mimics receptors by activating GTP-biding regulatory proteins (G proteins)”. Journal of Biological Chemistry 263 (1988): 6491-6494.
33. Lagerström MC and Schiöth HB. “Structural diversity of G protein-coupled receptors and significance for drug discovery”. Nature Reviews Drug Discovery 7 (2008): 339-357.
34. Thathiah A and De Strooper B. “The role of G protein-coupled receptors in the pathology of Alzheimer’s Disease”. Nature Reviews Neuroscience 12 (2011): 73-87.
35. Guixa-Gonzalez R., et al. “Crosstalk within GPCR heteromers in schizophrenia and Parkinson’s Disease: Physical or just functional?” Current Medicinal Chemistry 19 (2012): 1119-1134.
36. González-Maeso J., et al. “Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: Selective supersensitivity of alpha(2A)-adrenoceptors”. Molecular Psychiatry 7 (2002):  755-767.
37. Nakajima T., et al. “Amphiphilic peptides in wasp venom”. Biopolymers 25 (1986): S115-S121.
38. Konno K., et al. “Identification of bradykinins in solitary wasp venoms”. Toxicon 40 (2002): 309-312.
39. Picolo G., et al. “Bradykinin-related peptides in the venom of the solitary wasp Cyphononyx fulvognathus”. Biochemical Pharmacology 79 (2010): 478-486.
40. Rocha e Silva M., et al. “Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin”. American Journal of Physiology 156 (1949): 261-273.
41. Moreau ME., et al. “The kallikrein-kinin system: Current and future pharmacological targets”. Journal of Pharmacological Sciences 99 (2005):  6-38.
42. Piek T., et al. “Block of synaptic transmission in insect CNS by toxins from the venom of the wasp Megascolia flavifrons (Fab.)”. Comparative Biochemistry and Physiology C 87 (1987): 287-295.
43. Noda M., et al. “Neuroprotective role of bradykinin because of the attenuation of pro-inflammatory cytokine release from activated microglia”. Journal of Neurochemistry 101 (2007): 397-410.
44. Golias Ch., et al. “The kinin system—Bradykinin: Biological effects and clinical implications. Multiple role of the kinin system—Bradykinin”. Hippokratia 11 (2007): 124-128. 
45. Thornton E., et al. “Kinin receptor antagonists as potential neuroprotective agents in central nervous system injury”. Molecules 15 (2010): 6598-6618.
46. Yasuyoshi H., et al. “Protective effect of bradykinin against glutamate neurotoxicity in cultured rat retinal neurons”. Investigative Ophthalmology and Visual Science 41 (2000): 2273-2278.
47. Mortari MR., et al. “Inhibition of acute nociceptive responses in rats after i.c.v. injection of Thr6-bradykinin, isolated from the venom of the social wasp, Polybia occidentalis”. Bharatiya Janata Party 151 (2007):  860-869.
48. Pellegrini M and Mierke DF. “Threonine6-bradykinin: Molecular dynamics simulations in a biphasic membrane mimetic”. Journal of Medicinal Chemistry 40 (1997): 99-104.
49. Strømgaard K., et al. “Recent Advances in the Medicinal Chemistry of Polyamine Toxins”. Mini-Reviews in Medicinal Chemistry 1 (2001): 317-338.
50. Andersen TF., et al. “Uncompetitive Antagonism of AMPA Receptors: Mechanistic Insights from Studies of Polyamine Toxin Derivatives”. Journal of Medicinal Chemistry 49 (2006): 5414-5423.
51. Eldefrawi AT., et al. “Structure and synthesis of a potent glutamate receptor antagonist in wasp venom”. Proceedings of the National Academy of Sciences of the United States of America 85 (1988): 4910-4913.
52. Mellor IR and Usherwood PNR. “Targeting ionotropic receptors with polyamine-containing toxins.
53. Strømgaard K., et al. “Polyamine toxins: Development of selective ligands for ionotropic receptors”. Toxicon 45 (2005): 249-254.
54. Strømgaard K and Mellor I. “AMPA Receptor Ligands: Synthetic and Pharmacological Studies of Polyamines and Polyamine Toxins”. Medicinal Research Reviews 24 (2004): 589-620.
55. Traynelis SF., et al. “Glutamate Receptor Ion Channels: Structure, Regulation, and Function”. Pharmacological Reviews 62 (2010): 405-496.
56. Lemoine D., et al. “Ligand-Gated Ion Channels: New Insights into Neurological Disorders and Ligand Recognition”. Chemical Reviews 112 (2012): 6285-6318.
57. Poulsen MH., et al. “Inhibition of AMPA Receptors by Polyamine Toxins is Regulated by Agonist Efficacy and Stargazin”. Neurochemical Research 39 (2014): 1906-1913.
58. Lipton SA. “Pathologically activated therapeutics for neuroprotection”. Nature Reviews Neuroscience 8 (2007): 803-808.
59. Johnson JW., et al. “Recent insights into the mode of action of memantine and ketamine”. Current Opinion in Pharmacology 20 (2015): 54-63.
60. Tikhonov DB. “Ion channels of glutamate receptors: Structural modelling”. Molecular Membrane Biology 24 (2007):135-147.
61. Nørager NG., et al. “Development of potent fluorescent polyamine toxins and application in labeling of ionotropic glutamate receptors in hippocampal neurons”. ACS Chemical Biology 8 (2013): 2033-2041.
62. Danielisová V., et al. “Effects of bradykinin postconditioning on endogenous antioxidant enzyme activity after transient forebrain ischemia in rat”. Neurochemical Research 33 (2008): 1057-1064.
63. Danielisová V., et al. “Bradykinin postconditioning protects pyramidal CA1 neurons against delayed neuronal death in rat hippocampus”. Cellular and Molecular Neurobiology 29 (2009): 871-878.
64. Conn HJ. “Staining procedures used by the biologi- cal stain commission of polybia-MPI, a novel anti- microbial peptide, in multi-drug resistant leukemic cells”. Cancer Letters 278 (1960): 65-72.
65. Wu T and Li M. “The cytolytic action of all-D masto- paran M on tumor cell lines”. International Journal of Tissue Reactions 21.2 (1999): 35-42.
66. Lin C., et al. “Efficacy of mastoparan-AF alone and in combination with clinically used antibiotics on nosocomial multidrug-resistant acinetobacter baumannii”. Saudi Journal of Biological Sciences 24.5 (2017): 1023-1029.
67. Bechara C and Sagan S. “Cell-penetrating peptides: 20 years later, where do we stand?”. FEBS Letters 587.12 (2013):1693-1702.
68. Copolovici DM., et al. “Cell-penetrating peptides: Design, synthesis, and applications”. ACS Nano 8.3 (2014): 1972-1994.

Citation

Citation: Mamdouh Ibrahim Nassar and Emad Mahmoud Elzayat. “Anti-cancer and Anti-microbial and Neurological Effects Using Wasp Venom Peptides Agent: Review". Acta Scientific Microbiology 3.1 (2020): 97-102.

Copyright

Copyright: © 2020 Mamdouh Ibrahim Nassar and Emad Mahmoud Elzayat. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.